Pharma determines access, pricing, supply, and exits, the four pillars of GLP-1 market stability.(e.g., Roche, AbbVie, Novo Nordisk) They control the drug pipeline and reimbursement Pharmas licensing, M&A, and distribution decisions determine what products clinicians can prescribe and what insurers will cover
The primary outcome of AF readmission and all secondary outcomes were assessed at 2 years excluding an initial 90-day blanking period
A composite example from my practice: Ive cared for a patient maximized on both a DMARD and a biologic, still flaring several times a month, exhausted, in pain
Over time, this causes hard spots under the skin that do not absorb medication well
Proc Natl Acad Sci 102:491496